The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 36 results:
Author Title Type [ Year(Desc)]
Filters: Keyword is Receptor, ErbB-2  [Clear All Filters]
2006
Bobos, M., Hytiroglou P., Kostopoulos I., Karkavelas G., & Papadimitriou C. S. (2006).  Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung.. Am J Dermatopathol. 28(2), 99-104.
2009
Zafrakas, M., Zepiridis L., Theodoridis T. D., Venizelos I. D., Papanicolaou A., Agorastos T., et al. (2009).  ERBB2 (HER2) protein expression in uterine sarcomas.. Eur J Gynaecol Oncol. 30(3), 292-4.
Christodoulou, C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., et al. (2009).  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.. Oncology. 76(4), 275-85.
2010
Ihnen, M., Wirtz R. M., Kalogeras K. T., Milde-Langosch K., Schmidt M., Witzel I., et al. (2010).  Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.. Br J Cancer. 103(7), 1048-56.
Koletsa, T., Kotoula V., Karayannopoulou G., Nenopoulou E., Karkavelas G., Papadimitriou C. S., et al. (2010).  EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.. Histol Histopathol. 25(9), 1171-9.
Antoniou, A. C., Wang X., Fredericksen Z. S., McGuffog L., Tarrell R., Sinilnikova O. M., et al. (2010).  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.. Nat Genet. 42(10), 885-92.
Gogas, H., Pectasides D., Kostopoulos I., Lianos E., Skarlos D., Papaxoinis G., et al. (2010).  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.. Clin Breast Cancer. 10(3), 230-7.
Bamias, A., Karina M., Papakostas P., Kostopoulos I., Bobos M., Vourli G., et al. (2010).  A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.. Cancer Chemother Pharmacol. 65(6), 1009-21.
2011
Razis, E., Bobos M., Kotoula V., Eleftheraki A. G., Kalofonos H. P., Pavlakis K., et al. (2011).  Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.. Breast Cancer Res Treat. 128(2), 447-56.
2012
Stevens, K. N., Fredericksen Z., Vachon C. M., Wang X., Margolin S., Lindblom A., et al. (2012).  19p13.1 is a triple-negative-specific breast cancer susceptibility locus.. Cancer Res. 72(7), 1795-803.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Skarlos, P., Christodoulou C., Kalogeras K. T., Eleftheraki A. G., Bobos M., Batistatou A., et al. (2012).  Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.. Cancer Chemother Pharmacol. 69(2), 533-46.
2013
Batistatou, A., Televantou D., Bobos M., Eleftheraki A. G., Kouvaras E., Chrisafi S., et al. (2013).  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.. Anticancer Res. 33(5), 2139-45.
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Martin, V., Landi L., Molinari F., Fountzilas G., Geva R., Riva A., et al. (2013).  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.. Br J Cancer. 108(3), 668-75.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Kotoula, V., Kalogeras K. T., Kouvatseas G., Televantou D., Kronenwett R., Wirtz R. M., et al. (2013).  Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.. Virchows Arch. 462(2), 141-54.
2014
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Toesca, A., Botteri E., Lazzeroni M., Vila J., Manika A., Ballardini B., et al. (2014).  Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.. Breast. 23(6), 829-35.
Ellina, M-I., Bouris P., Aletras A. J., Theocharis A. D., Kletsas D., & Karamanos N. K. (2014).  EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules.. Biochim Biophys Acta. 1840(8), 2651-61.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.